GI Oncology Daily Digest

For nearly a decade, hepatologists have argued over whether curing hepatitis C with direct-acting antivirals (DAAs) is safe in patients who already have hepatocellular carcinoma (HCC), after early single-center reports raised alarm about accelerated tumor recurrence. This systematic review and meta-analysis pools 88 studies and 8,839 patients with HCC treated with DAAs to settle the question with scale. The pooled sustained virologic response (SVR) was 89% (95% CI 87-91%), somewhat lower than in patients without HCC (risk ratio 0.95) and dependent on tumor viability — 91% in non-viable HCC, 88% in mixed, and 84% in viable tumors — a reminder that active tumor burden modestly blunts antiviral efficacy. The recurrence signal, however, ran firmly in the opposite direction from the old fears: across 28 studies reporting recurrence, DAA-treated patients had a 40% lower recurrence risk than untreated patients (RR 0.60, 95% CI 0.49-0.75), and pooled adjusted estimates showed DAA therapy was independently associated with reduced recurrence (HR 0.47, 95% CI 0.32-0.70) and reduced all-cause mortality (HR 0.40, 95% CI 0.31-0.51). Achieving SVR itself tracked with lower recurrence (HR 0.43). The clinical bottom line is reassuring and actionable: antiviral therapy should not be withheld from patients with HCV-related HCC — DAAs are effective and, far from promoting recurrence, are associated with fewer recurrences and longer survival.

Total neoadjuvant therapy (TNT) is now standard for locally advanced rectal cancer, but the optimal sequence and duration remain unsettled. KCSG CO 14-03 is a multicenter randomized trial that had earlier shown improved short-term pathologic outcomes when two cycles of consolidation capecitabine-oxaliplatin (CAPOX) were added after preoperative chemoradiation; this report delivers the 7-year long-term follow-up. Among 110 patients with cT3-4 disease randomized to chemoradiation alone (arm A) or chemoradiation followed by consolidation CAPOX (arm B), 7-year disease-free survival was 61.2% versus 75.6% (hazard ratio 0.59, 95% CI 0.28-1.21, P=.148), and 7-year overall survival was 78.9% versus 83.2% (HR 0.75, 95% CI 0.27-2.08, P=.587). Distant recurrence after total mesorectal excision was numerically lower with consolidation (21.8% vs 29.9%), as was locoregional recurrence (4.0% vs 6.1%). The trade-off was quality of life: FACT-C total, physical, and functional well-being scores dropped significantly more in the consolidation arm before surgery, though that difference disappeared after surgery. The honest read is that this small phase-2-sized trial shows a consistent numerical DFS advantage for consolidation chemotherapy that did not reach statistical significance — hypothesis-supporting for consolidation-based TNT rather than practice-defining, and a useful long-term data point as the field debates induction versus consolidation sequencing.

Triplet chemotherapy (FOLFOXIRI) is normally reserved for metastatic colorectal cancer, but intensifying the systemic component of total neoadjuvant therapy could improve tumor response and reduce distant relapse in high-risk locally advanced rectal cancer (LARC) — if patients can actually tolerate it. The Dutch national multicenter phase 2 MEND-IT trial tested neoadjuvant FOLFOXIRI followed by chemoradiation in this population; this report focuses on the secondary feasibility and toxicity outcomes. Of 128 enrolled patients, 124 were evaluable. Treatment delivery held up well: 116 patients (93.5%) completed at least four FOLFOXIRI cycles plus chemoradiation, and 102 (82.3%) completed all six cycles plus chemoradiation, with no patient unable to start chemoradiation because of chemotherapy toxicity. Intensity came at a predictable price — dose reductions were required in 54% of patients (most often oxaliplatin, 47.6%) — but serious toxicity remained bounded: grade 3-or-higher serious adverse events and adverse events (or grade 4-or-higher hematologic) occurred in 37.1% of patients, with serious adverse events in 25%; diarrhea (26.9%) and nausea (17.9%) were the most frequent events. The authors conclude that triplet-based TNT is feasible with manageable toxicity and high completion rates in well-selected high-risk LARC, and call for randomized trials to weigh its efficacy and toxicity against other TNT regimens. The trial's primary complete-response endpoint is reported separately.

Most intestinal-type gastric cancer develops through a stepwise sequence that begins with pyloric (spasmolytic polypeptide-expressing metaplastic, or SPEM) metaplasia, in which mature gastric chief cells transdifferentiate into a pre-cancerous metaplastic lineage. This study identifies the transcription factor SOX9 as the master regulator of that transition. SOX9 was highly expressed in SPEM cells in both human and mouse metaplasia, so the authors deleted it using two chief-cell-specific Sox9-knockout mouse models, including one carrying oncogenic KrasG12D. The results were striking: without SOX9, chief cells simply failed to transdifferentiate into SPEM cells, so metaplasia did not develop after either acute or chronic mucosal injury, and — critically — the Kras-driven model failed to progress through carcinogenesis, with glands instead repopulating normal homeostatic gastric lineages. Single-cell RNA sequencing pinpointed a TOP2A-expressing SPEM subpopulation responsible for metaplasia progression and for recruiting fibroblasts to gland bases, and the team confirmed SOX9's role in human tissue microarrays and SPEM organoids. Because SPEM metaplasia is the rate-limiting pre-malignant step in a cancer that is still frequently caught late, a druggable master switch that can halt or reverse metaplastic progression is an appealing chemoprevention and interception target — this is preclinical work, but it is a clean mechanism-to-target story in gastric carcinogenesis.